麦澜德8月28日获融资买入1469.10万元，融资余额1.59亿元

Core Insights - 麦澜德's stock price decreased by 1.51% on August 28, with a trading volume of 151 million yuan [1] - The company reported a financing buy-in of 14.69 million yuan and a financing repayment of 22.95 million yuan on the same day, resulting in a net financing outflow of 8.26 million yuan [1] - As of August 28, the total margin balance for 麦澜德 was 159 million yuan, representing 10.19% of its circulating market value, which is above the 90th percentile level over the past year [1] Financing and Margin Data - On August 28, 麦澜德 had a financing buy-in of 14.69 million yuan, with a current financing balance of 159 million yuan [1] - The margin trading data indicates that 麦澜德 had no short selling activity on that day, with a short selling balance of 0 [1] Company Overview - 南京麦澜德医疗科技股份有限公司 was established on January 16, 2013, and went public on August 11, 2022 [1] - The company's main business involves the research, development, production, sales, and service of products related to pelvic floor and postpartum rehabilitation [1] - The revenue composition of 麦澜德 includes pelvic floor rehabilitation (39.39%), consumables and accessories (28.12%), reproductive rehabilitation (25.81%), sports rehabilitation (4.25%), and other products (2.42%) [1] Financial Performance - For the first half of 2025, 麦澜德 reported a revenue of 241 million yuan, a year-on-year increase of 5.62%, while the net profit attributable to shareholders decreased by 11.96% to 63.92 million yuan [2] - Since its A-share listing, 麦澜德 has distributed a total of 268 million yuan in dividends [2] Shareholder Structure - As of June 30, 2025, 麦澜德 had 5,461 shareholders, an increase of 10.84% from the previous period [2] - The average number of circulating shares per shareholder was 6,743, a decrease of 9.78% [2] - Notable changes in institutional holdings include 华夏稳增混合 increasing its stake by 14.17% to 1.25 million shares, while several funds exited the top ten shareholders list [2]